Molecular mechanisms of resistance and toxicity associated with platinating agents

Cara A. Rabik, M. Eileen Dolan

Research output: Contribution to journalReview article

Abstract

Platinating agents, including cisplatin, carboplatin, and oxaliplatin, have been used clinically for nearly 30 years as part of the treatment of many types of cancers, including head and neck, testicular, ovarian, cervical, lung, colorectal and relapsed lymphoma. The cytotoxic lesion of platinating agents is thought to be the platinum intrastrand crosslink that forms on DNA, although treatment activates a number of signal transduction pathways. Treatment with these agents is characterized by resistance, both acquired and intrinsic. This resistance can be caused by a number of cellular adaptations, including reduced uptake, inactivation by glutathione and other anti-oxidants, and increased levels of DNA repair or DNA tolerance. Here we investigate the pathways that treatment with platinating agents activate, the mechanisms of resistance, potential candidate genes involved in the development of resistance, and associated clinical toxicities. Although the purpose of this review is to provide an overview of cisplatin, carboplatin, and oxaliplatin, we have focused primarily on preclinical data that has clinical relevance generated over the past five years.

Original languageEnglish (US)
Pages (from-to)9-23
Number of pages15
JournalCancer Treatment Reviews
Volume33
Issue number1
DOIs
StatePublished - Feb 1 2007
Externally publishedYes

Keywords

  • Cisplatin
  • DNA damage
  • Drug resistance

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Molecular mechanisms of resistance and toxicity associated with platinating agents'. Together they form a unique fingerprint.

  • Cite this